Literature DB >> 8606630

Remission of systematic lupus erythematosus.

C Drenkard1, A R Villa, C Garcia-Padilla, M E Pérez-Vázquez, D Alarcón-Segovia.   

Abstract

The occurrence and characteristics of remissions in patients with systematic lupus erythematosus (SLE) have not been determined. We therefore studied this in a cohort of 667 patients and found that 156 patients had achieved at least 1 period of 1 year or more of treatment-free clinical remission. This represents an incidence density of 0.028 new cases/person/year. Remission occurred within the first 2 years of disease in 62 patients. The mean duration of first remission was 4.6 years (range, 1-21 yr), and 81 patients were still in the initial remission up until cutoff time. Half of the remaining 75 patients who flared after achieving remission have not entered again in remission. Twenty-six of the 38 patients who did remained in remission, and the remaining 12 had subsequent flares and remissions. Treatment-free remission accounted for a mean of 5.8 years, corresponding to half the time of follow-up. Remission was not limited to patients with mild disease: at least 41 patients achieved remission despite renal involvement, 19 had had neuropsychiatric lupus, 15 had had thrombocytopenia, and 8 had had hemolytic anemia. We also found that the longer the time lapse between the initial manifestation and the diagnosis of SLE, the less likely it was for a patient to enter into remission. There was a continuous increase in likelihood of achieving a first remission from the beginning of disease up to 30 years of disease duration, when it reached 70%. Patients who achieved remission had increased survival, independently of the effect of other disease manifestations that cause increased mortality. We conclude that a significant proportion of patients with SLE, including those with severe organ involvement, may become symptom-free and in need of no more medication, perhaps indefinitely. Our findings support the notion that, in general, SLE is a more benign disease than previously considered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606630     DOI: 10.1097/00005792-199603000-00005

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  16 in total

1.  Impact of follow-up visits on disease outcome in Chinese systemic lupus erythematosus.

Authors:  Huanhuan Ma; Jing Dong; Liqin Wang; Lei Zhao; Lin Pan
Journal:  Clin Rheumatol       Date:  2017-08-03       Impact factor: 2.980

2.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

3.  Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.

Authors:  Hironari Hanaoka; Harunobu Iida; Tomofumi Kiyokawa; Yukiko Takakuwa; Kimito Kawahata
Journal:  Clin Rheumatol       Date:  2019-06-07       Impact factor: 2.980

Review 4.  Treat to target in systemic lupus erythematosus: a commentary.

Authors:  Manuel F Ugarte-Gil; Paula I Burgos; Graciela S Alarcón
Journal:  Clin Rheumatol       Date:  2016-07-12       Impact factor: 2.980

Review 5.  Remission and withdrawal of therapy in lupus nephritis.

Authors:  Gabriella Moroni; Francesca Raffiotta; Claudio Ponticelli
Journal:  J Nephrol       Date:  2016-05-04       Impact factor: 3.902

6.  Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX.

Authors:  J Zhang; L A González; J M Roseman; L M Vilá; J D Reveille; G S Alárcon
Journal:  Lupus       Date:  2010-01-29       Impact factor: 2.911

7.  Factors associated with remission in patients with systemic lupus erythematosus: new insights into a desirable state.

Authors:  Jorge Romo-Tena; Roberto Reyna-de la Garza; Isaac Bartnicki-Navarrete; Jorge Alcocer-Varela; Diana Gómez-Martin
Journal:  Clin Rheumatol       Date:  2018-07-28       Impact factor: 2.980

8.  Inactive disease and remission in childhood-onset systemic lupus erythematosus.

Authors:  Rina Mina; Marisa S Klein-Gitelman; Angelo Ravelli; Michael W Beresford; Tadej Avcin; Graciela Espada; B Anne Eberhard; Laura E Schanberg; Kathleen M O'Neil; Clovis A Silva; Gloria C Higgins; Karen Onel; Nora G Singer; Emily von Scheven; Lisa F Imundo; Shannen Nelson; Edward H Giannini; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

9.  Patient Perspective on Using Digital Resources to Address Unmet Needs in Systemic Lupus Erythematosus.

Authors:  Jennifer H Ra; Jerik Leung; Elizabeth A Baker; Alfred H J Kim
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-08       Impact factor: 5.178

10.  Targeting plasma cells in autoimmune diseases.

Authors:  David M Tarlinton; Philip D Hodgkin
Journal:  J Exp Med       Date:  2004-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.